Intravenous buprenorphine/naloxone and concomitant oral pregabalin misuse: a case report

por Kulaksizoğlu B, Kara H, Bodur B, Kuloğlu M
Publicado 2018

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia

por Albayarak Y, Akyol ES, Beyazyüz M, Baykal S, Kuloglu M
Publicado 2015

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

por Ünsal C, Albayrak Y, Albayrak N, Kuloğlu M, Hashimoto K
Publicado 2013

Reduced serum brain-derived neurotrophic factor in patients with first onset vitiligo

por Yanik ME, Erfan G, Albayrak Y, Aydin M, Kulac M, Kuloglu M
Publicado 2014

Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome

por Akyol ES, Albayrak Y, Beyazyüz M, Aksoy N, Kuloglu M, Hashimoto K
Publicado 2015

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study

por Beyazyüz M, Küfeciler T, Bulut L, Ünsal C, Albayrak Y, Akyol ES, Baykal S, Kuloglu M, Hashimoto K
Publicado 2016